| Class |
Compound |
HDAC target |
Phase |
Company |
Condition tested in Clinical Trials |
| Hydroxamic acid |
Zolinza, vorinostat (SAHA) |
Classes I and II |
FDA |
Merck |
Approved for CTCL, phase I/ II for gastric cancer, NSCLC, thyroid cancer and
advanced cancers |
| Panobinostat (LBH589) |
Classes I and II |
III |
Novartis |
Phase III trial for CTCL and phase II for CML, MM, NHL, HL, BC, chordoma, prostate
and others advanced solid tumors |
| Belinostat (PXD101) |
Classes I and II |
II |
TopoTarget |
Relapsed ovarian cancer, TCL, thymoma, thymic carcinoma, MM, NSCLC, brain tumors |
| Givinostat or Gavinostat (ITF2357) |
Classes I and II |
II |
Italfarmaco |
Relapsed leukemias and MM |
| Trichostatin (TSA) |
Classes I and II |
N/C |
N/C |
N/C |
| Abexinostat (PCI-24781) |
Classes I and II |
II |
Pharmacyclics |
BCL, sarcoma |
| LAQ-824 |
Classes I and II |
I |
Novartis |
Solid and hematologic malignancies |
| Pracinostat (SB939) |
Classes I, II and SIRT 1 |
II |
MEI Pharma |
Prostate cancer, solid tumors, hematologic malignancies |
| JNJ-26481585 |
HDAC1, HDAC6 |
I |
Johnson & Johnson |
Leukemia, CTCL and solid tumors |
| CUDC-101 |
Classes I and II |
I |
Curis |
Head and neck, gastric, BC, liver cancer, MM, NSCLC |
| CHR-3996 |
Class I |
I |
Chroma Therapeutics |
Solid tumors |
| CHR-2845 |
Class I |
I |
Chroma Therapeutics |
Hematological diseases or lymphoid malignancies |
| Quisinostat (JNJ 26481585) |
Class I |
II |
MedKoo bioscience |
CTCL, MM |
| CG200745 |
Pan-HDAC |
I |
CrystalGenomics, Inc, |
Solid tumors |
| Rocilinostat (ACY-1215) |
HDAC6 |
I and II |
MedKoo bioscience |
MM |
| Benzamides |
Entinostat (MS-275 SNDX275) |
HDAC1,HDAC2,HDAC3 |
II |
Schering |
HL, lung cancer, ALL, BC, melanoma and advanced solid tumors |
| Mocetinostat (MGCD0103) |
HDAC1 and HDAC2 |
II |
Methylgene |
AML |
| Tacedinaline (CI-994) |
HDAC1 and HDAC2 |
II and III |
Parke-Davis Pharmaceutical |
MM, pancreatic cancer, phase III for Lung Cancer |
| AR-42 |
Pan-HDAC |
I |
Arno Therapeutics |
MM, CLL or lymphoma |
| 4SC-202 |
HDAC1, HDAC2, HDAC3 |
I |
MedKoo bioscience |
Hematological malignancies |
| Resminostat (4SC-201) |
Classes I and II |
I and II |
MedKoo bioscience |
Hepatocellular carcinoma , colorectal cancer and HL |
| Cyclic Peptides |
Romidepsin/Istodax |
HDAC1 and HDAC2 |
FDA |
Celgene |
Aproved for CTCL |
| (FK228 and FR901228) |
| Aliphatic Acids |
Valproic Acid |
Classes I and IIa |
II and III |
Abbot |
Phase III trials for cervical cancer, ovarian cancer and phase II for sarcomas, BC,
malignant melanoma, AML, brain tumors and advanced cancers |
| Phenylbutyrate (PB) |
Classes I and IIa |
I and II |
Targon Corporation |
Colorectal cancer, malignant gliomas, solid tumors, leukemias, lymphomas |
| Butyrate |
Classes I and IIa |
I, II
and III |
|
Lymphoproliferative disorders, prostate cancer or other solid tumors, phase III for
ovarian cancer |
|
